Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Mirtazapine Orally Disintegrating Tablets USP in strengths of 15 mg, 30 mg & 45 mg. The drug is an anti-depressant and will be produced at the group's formula ions manufacturing facility at Baddi.
The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
